Ra Capital Management, L.P. bought $46.6M of Bambusa Therapeutics (BBTX)
Executed Oct 30, disclosed Nov 3, 4 days later.
Not yet measured: the 21-session window has not closed, or the prices around it are not on record.
Ra Capital Management, L.P. (Director) filed 31 Form 4 reports as a reporting entity in the trailing twelve months (23 purchases, 8 sales, 1 filed past the two-business-day deadline), most often in Artiva Biotherapeutics, Inc. (ARTV). Across 22 priced purchase filings, the average 21-session return was +16.2% from execution and +14.2% from disclosure (delay-adjusted; derived). The largest single filing was $423.8M of PBLS (21,188,750 sh across 2 lots, as filed), executed Jun 11.
Healthcare · Bambusa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops long-acting bispecific antibodies for the treatment of imm…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→